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Objective: To analyze the mechanism(s) underlying homograft degeneration, we 
designed an experimental model in which the behavior of cryopreserved 
autografts and homografts, as well as fresh autografts, implanted in the same 
animal was compared. Methods: A cryopreserved homograft was implanted in 
the aorta of 14 sheep. The excised aortic autologous egment was then 
subjected to cryopreservation, a d 1 to 8 weeks later it was implanted 1to 2 cm 
below the cryopreserved homograft. The intermediate segment of the native 
aorta, the fresh autograft, was dissected at this point. Animals were put to 
death at different imes and the implanted segments were harvested together 
with a portion of native aorta. Histologic and immunohistochemical analyses, 
as well as cell viability assessments, were then performed on the explanted 
segments. Similar studies were also conducted on fragments of cryopreserved 
autografts and homografts before implantation. Results: With the exception of 
a partial loss of the endothelium, cryopreserved specimens retained cell 
viability and morphologic integrity before implantation. Explanted cryopre- 
served homografts showed profound changes affecting all strata, as well as a 
decline in cell viability. Lymphocyte infiltrates were found up to 12 months 
after implantation. Endothelium was always absent in cryopreserved ho- 
mografts. However, a reendothelialization of the cryopreserved autografts was 
observed. After an initial period of neuronal degeneration, reenervation of the 
cryopreserved autograft segment occurred 6 to 12 months after the operation. 
Findings regarding the fresh autografts were similar to those of the cryopre- 
served autografts. Conclusion: Our results suggest that the immunologic 
reaction rather than the cryopreservation process is responsible for the 
degenerative process occurring in cryopreserved homografts. (J Thorac Car- 
diovasc Surg 1997;113:1014-21) 
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C ryopreserved homograft heart valves and con- duits are frequently used in the surgical correc- 
tion of several diseases, in which they remain the 
substitutes of choice. However, the mechanisms 
underlying the degenerative process that ultimately 
leads to their failure remain unknown. 
Recent studies comparing heart valve homografts 
and valves of transplanted hearts showed that 
whereas the latter contained fibroblasts of both 
donor and recipient origin, the former were acellu- 
lar. 1-3 These differences could be due to either the 
occurrence of an immune response in homograft  
valve recipients, which was prevented or abrogated 
by the immunosuppressive therapy administered to 
heart transplant recipients but not to homograft 
valve recipients, or to the cryopreservation process 
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Fig. 1. Cryostat sections of sheep native aorta (NA; parts A, E, I, and M), fresh autografts (FA; parts C, 
G, K, and O), and aortic cryopreserved homografts (CH; parts B, F, J, and N) and autografts (CA; parts 
D, H, L, and P) 3 months after implantation i  the same animal. Preparations were immunostained for the 
yon Willebrand factor (VWF; parts A, B, C, and D), s-smooth muscle actin (ACTIN; parts E, F, G, and H), 
protein gene product 9.5 (PGP9.& parts I, J, K, and L), and S-100 (parts M, N, O, and P). (A, B, C, and 
D, original magnification ×272; E through P, original magnification ×136.) 
to which the homograft valves were subjected. To 
distinguish between these two alternatives, we 
designed an experimental model in which the 
behavior of cryopreserved autografts and ho- 
mografts, implanted in the same animal, was 
compared. Fresh autografts were used to analyze 
the role of denervation and devascularization. 
The biologic alterations induced by the different 
procedures were assessed by evaluation of cell 
viability and by immunohistochemical analysis of 
the endothelium, perivascular innervation, and 
medial smooth muscle cells. Genetic profiles of 
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Fig. 2. Cryostat sections of sheep native aorta (NA; parts A, E, I, and M), fresh autografts (FA; parts C, 
G, K, and O), and aortic cryopreserved homografts (CH; parts B, F, J, and N) and autografts (CA; parts 
D, H, L, and P) 2 years after implantation i the same animal. Preparations were immunostained for the 
von Willebrand factor (VWF; parts A, B, C, and D), s-smooth muscle actin (ACT1N; parts E, F, G, and H), 
protein gene product 9.5 (PGP9.5; parts I, J, K, and L), and S-100 (parts M, N, O, and P). (A, B, C, and 
D, original magnification ×272; E through P, original magnification x136.) 
donor and recipient cells were used to determine the 
origin of the cells in explanted cryopreserved ho- 
mografts. 
Material and methods 
Animals. Fifteen Merino Branco sheep, eight ewes and 
seven rams, aged 2 to 18 months, were used. 
Surgery. Standard anesthesia technique with thiopen- 
tal sodium (Pentothal) and halothane was used. Humane 
care was provided to all animals during the experiment, in
compliance with the "Guide for the Care and Use of 
Laboratory Animals" (NIH publication No. 86-23, revised 
1985). Cryopreserved homografts of the descending tho- 
racic aorta were prepared as previously described.I: 2 In 
the first operation, a 1 to 2 cm segment of thoracic aorta 
was replaced by a cryopreserved homograft. The excised 
aortic segment was then Subjected to the same cry0preser- 
vation process used for treatment of the homografts. One 
to 8 weeks later, the cryopreserved autograft was im- 
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planted 1 to 2 cm below the cryopreserved homograft. The 
intermediate segment of the native aorta was, at this 
point, completely dissected from the surrounding tissues 
and used as a fresh autograft. Animals were put to death 
at different imes (2 weeks, 1, 3, 6, 12, and 24 months) 
after the second operation and the implanted segments 
were harvested together with a portion of native aorta to 
be used as control tissue. With regard to the latter 
segment, care was taken to analyze areas that were far 
from the surgical sites. 
Immunohistoehemistry. Immediately after excision, 
the various segments were fixed by immersion according 
to the method of Steffanini, De Martino, and Zamboni 4 
for 18 to 24 hours at 4 ° C. After being rinsed in several 
changes of phosphate-buffered saline solution (0.01 
tool/L, pH 7.2) containing 15% sucrose, tissues were 
processed as cryostat sections for indirect immunofluores- 
cence staining together with antisera raised against 
o:-smooth muscle actin and neuronal markers (protein 
gene product 9.5), endothelial markers (von Willebrand 
factor), and Schwann cell markers (S-100). Primary anti- 
sera were obtained from Sigma Chemical Company, St. 
Louis, Missouri, except for the antiserum to protein gene 
product 9.5, which was obtained from Ultraclone, isle of 
White, United Kingdom. 
Cell viability. Initially, cell viability was evaluated by 
culturing tissue fragments in 10 ml flasks for 3 to 4 weeks 
in Dulbecco's modified medium at 37 ° C in an atmosphere 
containing 10% carbon dioxide and graded as 0 to 5, 
according to the rate of fibrobtast growth. Explanted 
fragments were also analyzed by a new method, devised to 
ascertain a less subjective valuation of cell viability. Thus 
8 to 12 fragments of 1 mm diameter, excised from each 
portion of the explanted conduit, were cultured in RPMI 
medium (Roswell Park Memorial Institute, Buffalo, N.Y.) 
containing 10% fetal calf serum, in 96-well microtiter 
plates, at 37 ° C in an atmosphere containing 5% carbon 
dioxide. Fibroblast growth was evaluated microscopically 
on days 4, 8, and 15 after initiation of cultures. Wells with 
five or more fibrobtasts were considered positive. The 
results were then expressed in percent of positive wells. 
Analysis of DNA hypervariable r gions. Cell origin was 
determined as previously described 1' 2 by analyzing the 
hypervariable (CA)n repeat regions from DNA of native 
aorta and cryopreserved homografts. In brief, DNA ob- 
tained from tissues by the standard proteinase K method, 
followed by phenol-chloroform extraction, was amplified 
by polymerase chain reaction with the use of oligonucle- 
otide primers for TGLA53, TGLA126, TGLA263, 
MGTG7, and MGTG4B loci (kindly provided by Applied 
Biosystems Division of Perkin-Elmer, Foster City, Calif.). 
The polymerase chain reaction amplification was per- 
formed in a model PE 9600 thermocycler and the products 
were electrophoresed in an automated DNA sequencer 
(model 373A, ABI Analytical). The size of the (CA)n 
amplimers was determined with the use of the GENE- 
SCAN 672 software (ABI Analytical). 
Results 
With the exception of a partial loss of endothelial 
cells, cryopreserved specimens retained cell viability 
and morphologic integrity before implantation. 
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Fig. 3. Cell viability expressed in percent positive wells in 
native aorta (NA), cryopreserved homograft (CH), fresh 
autograft (FA), and cryopreserved autograft (CA) ex- 
planted 2 years after implantation. Below the x-axis a 
schematic representation f the fragments, as they were 
implanted, is shown. 
The results obtained with the various markers 3 
months and 2 years after the last operation are 
shown in Figs. 1 and 2, respectively. These two time 
points illustrate the degenerative and regenerative 
processes that occurred during the course of the 
experiment (2 years). As can be seen, explanted 
cryopreserved homografts howed profound histo- 
logic changes that affected all strata, as well as 
decline in cell viability (Fig. 3). After an initial 
period of nonspecific inflammatory reaction, which 
in most cases subsided after 1 to 3 months, progres- 
sive neuronal and smooth muscle degeneration, as 
well as fragmentation of elastic fibers, was observed, 
leading in later stages (6 to 12 months) to the 
disappearance of the perivascular innervation, fibro- 
sis hyalinization, and calcification. Most likely as a 
result of this process, one cryopreserved homograft 
ruptured after 17 months. Polymorphonuclear cells 
disappeared after 1 to 3 months; lymphocyte infil- 
trates, however, persisted up to 2 years after implan- 
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Fig. 4. In allografts, lymphocyte infiltrates persisted up to 2 years after implantation. Allografts explanted 
at 8 days (A), 15 days (B), 1 month (C), and 2 years (D) show an initial period of nonspecific inflammatory 
reaction with polymorphonuclear cell infiltrates (A and B). After 1 to 3 months only lymphocytes were 
observed (C and D). (Hematoxylin and eosin stain; original magnification ×400.) 
tation (Fig. 4). Although endothelial cells were 
always absent in cryopreserved homografts, reendo- 
thelialization occurred in the cryopreserved autografts. 
After an initial inflammatory eaction, as in all other 
segments, nerve degeneration was observed in cryo- 
preserved autografts. At this point (15 to 30 days), 
signs of smooth muscle alteration were also present, as 
judged by the weakness of the immunoreactive stain- 
ing for actin. At 3 to 6 months and thereafter, smooth 
muscle cells and myofibrils had, however, recovered 
their normal structure, and progressive reenervation 
was observed, with reestablishment of the normal 
nervous tissue pattern being achieved 6 to 12 months 
after the operation. Histologically, a single alteration, 
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Fig. 5. Electrophoretogram of the polymerase chain reaction products with primers for TGLA53 of a 
homograft (case 25) explanted after 1 year. The abscissa indicates the size in base pairs (bp) and the 
ordinate indicates the fluorescence intensity. 
Table I. Origin of cells of cryopreserved homografts 
Markers and sizes 
TGLA263 TGLA53 TGLA126 MGTG7 MGTG4B 
Sheep 
Imp&nm- 
tion dine 
90 Tissue 121 127 129 144 146 149 155 157 161 127 133 135 274 277 280 1,72 
2 Receptor 5096 8159 86757 31786 72771 3585 
Donor 11900* 25250 38729 7111 9738 461228 11804 
Homografl 3040 3641 24397 19262 5225 15478 
1 Receptor 1348 3734 28414 44789 3628 7683 501 
Donor 2523 613 17969 5271 6248 450 
Homografl 1591 1308 28017 16270 35275 535 429 1492 2723 
*Peak area. 
consisting of an intimal thickening, was patent in these 
explants (see Fig. 2, D). Cell viability was similar to 
that of native aorta. 
With the exception of the thickening of the m- 
tima, the loss of endothelium, and the initial alter- 
ation of the smooth muscle cells, which did not 
occur in fresh autografts, the histologic and immu- 
nohistochemical findings in this fragment were sim- 
ilar to those of the cryopreserved autografts with 
regard to the kinetics of neuronal degeneration and 
regeneration. 
Origin of the cells in the cryopreserved ho- 
mografts was determined in fragments explanted 1
and 2 years after the operation. The results from 
these experiments showed that cells of both donor 
and recipient origin were present in the tissue in the 
first animal; and in the second only the latter were 
found (Table I and Fig. 5). 
Comment 
Even when performed under optimal conditions, 
harvesting, handling, cryopreservation, and antibi- 
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otic treatment of homografts affects the degree of 
cell survival, the metabolic rates of the viable cells, 
and, consequently, matrix degradation and synthe- 
sis. 5-14 Therefore, and despite the abundant evi- 
dence of immunogenicity of the valve homo- 
graft,l-3, 15-27 the concept that the durability of a 
homograft is related to the degree of cell viability at 
the time of implantation prevailed. 28-3° 
By creating conditions in which autologous tissue 
was treated in the same way as homologous tissue, 
we could ascertain that the preparation procedures, 
including ischemic time, antibiotic treatment, and 
cryopreservati0n, Were not responsible for the long- 
term deterioration found in homografts. 
Of particular interest were the findings that loss of 
the endothelium and degeneration of the neuronal 
tissue smooth muscle and vasa vasorum occurred in 
the cryopreserved autografts as it did in the ho- 
mografts. Thus the evidence that these processes 
were followed by regeneration i the former but not 
the latter further strengthens the concept hat the 
mechanism underlying the failure of the homografts 
is most likely immunologic rather than physical. 
Whether the immune response induced by the allo- 
geneic tissue led to the destruction of progenitor 
cells or prevented the release of angiogenic and 
neurogenic factors required for the regeneration 
process remains to be determined. 
More information on the origin of the cells in the 
homograft is needed before conclusions can be 
drawn. However, it is possible that at 2 years the 
donor cells have been destroyed and replaced by 
recipient cells. These findings are not consistent 
with those obtained in human heart valves. 1-3 This 
discrepancy might be due to the structural differ- 
ences between the two tissues, in particular the 
presence of muscular tissue in the aorta but not in 
the valve leaflets. 
Some of the findings in the present study may be 
clinically relevant. Thus it became clear that dener- 
vation and devascularization did not affect he vital- 
ity of the tissue, inasmuch as regeneration of both 
systems could occur, provided factors such as the 
immune response did not hinder the process. Such is 
the case of pulmonary autografts in the aortic root 
position (Ross operation). Also worth notice was 
the single alteration found in the cryopreserved 
autologous grafts, the thickening of the intima. 
Similar findings have been reported for cryopre- 
served rat aortic isografts. 26 Because intimal thick- 
ening did not occur in the fresh autologous frag- 
ments, it is tempting to hypothesize that this is the 
sole transformation i duced by cryopreservation. 
We are grateful to M. Castelo, M. R. Alpiar§a, R. 
Santos, P. Dias, G. Horak, and R. Cunha Ferreira for 
excellent technical assistance. We are also grateful to Dr. 
J. Ziegle from Perkin-Elmer Applied Biosystems Division 
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Discussion 
Dr. Patrick G. Hogan (Brisbane, Australia). I am asking 
my questions from the perspective of an immunologist. 
First, were you transplanting across a major histocompat- 
ibility complex barrier? What is known about the immu- 
nogenetics of the major histocompatibility complex in 
sheep? 
Dr. Neves. Yes. We were transplanting across the major 
histocompatibility complex. 
Dr. Hogan. The sheep are not likely to be inbred. They 
would be outbred. Might they be polymorphic for major 
hist0compatibility complex loci? 
Dr. Nevcs. Yes, but the same condition occurs in human 
beings. 
Dr. Hogan. I am interested in the S-100 staining. A 
recent paper from St. Vincent's Hospital in Australia, 
discussing the use of S-100, purports to show that there 
are dendritic ells in the human aorta. If immunologic 
responses are important, do you think any of your 
staining could have been produced by dendritic eils? I 
do note that there was no staining in the cryopreserved 
tissue. 
Dr. Neves. I am a surgeon, not an immunologist, and 
the information that I have from my colleagues i that 
S-100 stains the Schwann cells. I cannot answer that. 
Dr. Hogan. In your abstract, lymphocytic nfiltrates are 
documented asone point in favor of an immune response. 
Could you expand on that? Were the lymphocytic infil- 
trates different in intensity or nature in the homografts as 
opposed to the autografts? 
Dr. Neves. All of the segments in the first weeks have an 
inflammatory reaction. After 1 or 2 months, the ho- 
mograft persists with lymphocytes. We tried to mark them 
for T cells, B cells, and activations, but we had problems 
with the specific markers for sheep. It was difficult to get 
conclusions. However, we have performed these studies in 
human beings and we know that there is an immunologic 
response with activated T cells. 
